Physician profile
Christopher C Kyle
NPI 1205037587
$2,472.12
in general payments reported to CMS, 2019-2025
16 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $40.27 · 2021: $3.82 · 2023: $72.02 · 2024: $181 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745 · Travel and Lodging: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.71 |
| Travel and Lodging | $223.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,137.65 | 2019 | |
| Procept Biorobotics Corporation | $522.36 | 2025 | |
| Janssen Biotech, INC. | $353.52 | 2019-2025 | Erleada |
| Terumo Medical Corporation | $98.28 | 2024 | Glidesheath Slender |
| Abbvie INC. | $84.67 | 2024-2025 | |
| Urogpo LLC | $54.98 | 2019 | |
| Edap Technomed INC | $40.00 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $32.02 | 2023 | Lynparza |
| Urogen Pharma, INC. | $31.54 | 2025 | |
| Dendreon Pharmaceuticals LLC | $30.71 | 2025 | Provenge |
| Sumitomo Pharma America, INC. | $25.87 | 2025 | Orgovyx |
| Ferring Pharmaceuticals INC. | $23.93 | 2025 | Adstiladrin |
| Novartis Pharmaceuticals Corporation | $18.98 | 2024 | |
| Pfizer INC. | $13.79 | 2020 | |
| Travere Therapeutics, INC. | $3.82 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.